Pharmacokinetic evaluation of C-3 modified 1,8-naphthyridine-3-carboxamide derivatives with potent anticancer activity: lead finding

References

• FDA. News Drug Pipeline Alert. 2006;4:56
   Google Scholar
• Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:139–54
   PubMed Web of Science ®Google Scholar
• Tomita K, Tsuzuki Y, Shibamori K, et al. Synthesis and structure activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1-8-naphthyridine-3-caboxylic acids as antitumour agents. Part 1. J Med Chem 2002;45:5564–75
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Tomita K, Shibamori K, et al. Synthesis and structure activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1-8-naphthyridine-3-caboxylic acids as antitumour agents. J Med Chem 2004;47:2097–109
   PubMed Web of Science ®Google Scholar
• Baez A, Gonzalez FA, Vazquez D, Waring M. Interaction between a 3-nitrobenzothiazolo (3,2-a) quinolinium antitumour drug and deoxyribonucleic acid. Biochem Pharmacol 1983;32:2089--94
   PubMed Web of Science ®Google Scholar
• You QD, Li ZY, Huang CH, et al. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J Med Chem 2009;52:5649–61
   PubMed Web of Science ®Google Scholar
• Banti I, Nencetti S, Orlandini E, et al. Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. Pharm Pharmacol 2009;61:1057–66
   PubMedGoogle Scholar
• Atanasova M, Ilieva S, Galabov B. QSAR analysis of 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines with anticancer activity. Eur J Med Chem 2007;42:1184–92
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Jaggi M, Singh AT, et al. Anticancer and anti-inflammatory activities of 1,8-naphthyridine-3-carboxamide derivatives. Bioorg Med Chem Lett 2007;17:6660–4
   PubMed Web of Science ®Google Scholar
• Kumar V, Jaggi M, Singh AT, et al. 1,8-Naphthyridine-3-carboxamide derivatives with anticancer and anti-inflammatory activity. Eur J Med Chem 2009;44:3356–62
   PubMed Web of Science ®Google Scholar
• Kumar V, Madaan A, Sanna VK, et al. Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives. J Enzyme Inhib Med Chem 2009;24:1169–78
   PubMed Web of Science ®Google Scholar
• Kennedy T. Managing the drug discovery/development interface. Drug Discovery Tech 1997;2:436–44
   Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev 2004;3:711–15
   Google Scholar
• Masimirembwa CM, Bredberg U, Andersson TB. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 2003;42:515–28
   PubMed Web of Science ®Google Scholar
• Baranczewski P, Stanczak A, Sundberg K, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 2006;58:453–72
   PubMed Web of Science ®Google Scholar
• Yan Z, Caldwell GW. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem 2001;1:403–25
   PubMedGoogle Scholar
• Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7:165–82
   PubMed Web of Science ®Google Scholar
• Lv H, Wang F, Reddy MV, et al. Screening candidate anticancer drugs for brain tumour chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Invest New Drugs 2012;30:2263--73
   Google Scholar
• Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 2006;45:871–903
   PubMed Web of Science ®Google Scholar
• OECD Guidelines for the Testing of Chemicals, Section 1, Physical-Chemical properties. Test No. 107: Partition Coefficient (n-octanol/water): Shake Flask Method; 1995
   Google Scholar
• Schmidt D, Lynch J. Evaluation of the reproducibility of Parallel Artificial Membrane Permeation Assays (PAMPA) Millipore Protocol No. AN1728EN00, Millipore Corporation, USA, 2002. Available from: http://www.millipore.com/publications.nsf/docs/an1728en00 [last accessed 2002]
   Google Scholar
• Sugano K, Hamada H, Machida M, Ushio H. High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J Biomol Screen 2001;6:189–96
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. Use of in vitro human metabolism studies in drug development. Biochem Pharmacol 1994;48:2147–56
   PubMed Web of Science ®Google Scholar
• GENTEST Technical Bulletin. Methodology of a high throughput method for measuring cytochrome P450 inhibition. Woburn (MA): GENTEST Corporation; 1998
   Google Scholar
• Bansal T, Awasthi A, Jaggi M, et al. Pre-clinical evidence for altered absorption and billary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotien. Life Sci 2008;83:250–9
   PubMed Web of Science ®Google Scholar
• Troutman MD, Thakker DR. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res 2003;20:1192–9
   PubMed Web of Science ®Google Scholar
• Plowman J. Human tumour xenograft models in NCI drug development. In: Teicher B, ed. Anticancer drug development guide: preclinical screening, clinical trials, and approval. Totowa (NJ): Humana Press Inc; 1997:101–25
   Google Scholar
• Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004;40:827–36
   PubMed Web of Science ®Google Scholar
• Pliska V, Testa B, Waterbeemd H. Lipophilicity in drug action and toxicology. New York: John Wiley & Sons Ltd; 1996:439
   Google Scholar
• Sparreboom A, Nooter K, Loos WJ, Verweij J. The (ir) relevance of plasma protein binding of anticancer drugs. Neth J Med 2001;59:196–207
   PubMed Web of Science ®Google Scholar
• Baker SD, Li J, Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005;77:43–53
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokin 1994;27:216–48
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokin 1994;27:1–5
   PubMedGoogle Scholar
• Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokin 1986;11:23–235
   Google Scholar
• Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: do recent market removals mean there is a problem. JAMA 1999;281:1728–34
   PubMed Web of Science ®Google Scholar
• Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215–20
   PubMed Web of Science ®Google Scholar
• Irvine JD, Takahashi L, Lockhart K, et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 1999;88:28–33
   PubMed Web of Science ®Google Scholar
• Evanchik MJ, Allen D, Yoburn JC, et al. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin;formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos 2009;37:594–601
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Bargiotti A, Berthelsen J, et al. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumour agents. 2. Lead discovery. J Med Chem 2009;52:293–307
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Albanese C, Alli C, et al. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem 2010;53:7296–315
   PubMedGoogle Scholar